ALNYAlnylam Pharmaceuticals, Inc.

$42B

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$99M+198.8% YoY

Gross Profit

$86M86.6% margin

Operating Income

-$210M-211.3% margin

Net Income

-$182M-183.2% margin

EPS (Diluted)

$-1.62

QoQ Revenue Growth

+38.8%

Cash Flow

Operating Cash Flow

-$246M

Free Cash Flow

-$266M

Stock-Based Comp.

$35M

Balance Sheet

Total Assets

$2.3B

Total Liabilities

$930M

Stockholders' Equity

$1.3B

Cash & Equivalents

$468M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$99M	$33M	+198.8%
Gross Profit	$86M	$30M	+187.8%
Operating Income	-$210M	-$189M	-11.3%
Net Income	-$182M	-$182M	-0.2%

Revenue Segments

Product

$72M50%

ONPATTRO

$67M46%

GIVLAARI

$5M4%

Geographic Segments

UNITED STATES

$42M59%

Europe

$21M29%

Non-US Or Europe

$8M12%

ALNY Q1 2020 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena